Source link : https://www.newshealth.biz/health-news/zepbounds-weight-loss-cardiometabolic-benefits-hold-up-at-3-years/
SAN ANTONIO — Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of tirzepatide (Zepbound) and maintained that loss for more than 3 years, follow-up of a randomized trial showed. And patients taking any dose of the dual GLP-1/GIP receptor agonist had improvements in blood glucose, lipids, […]
Author : News Health
Publish date : 2024-11-07 20:39:01
Copyright for syndicated content belongs to the linked Source.
inHealth